Abstract:Abstract Background Vedolizumab (VDZ) is a gut-selective integrin inhibitor used to treat Crohn's disease (CD). Most of the information regarding real-life data on response to VDZ has been published from North America and Europe cohorts and there is scarce information from Latin America related to effectiveness of VDZ in patients with CD. The aims of this study were: i) to describe the clinical characteristics of patients with CD who received VDZ, ii) to know in which biologic line VDZ was indicated, and iii) to evaluate the clinical response at one year and the persistence of treatment during follow-up. Methods A retrospective multicenter study was conducted in 18 Argentinean centers. We included CD adult patients (age ≥18y) who started VDZ between 01/06/2015 and 31/10/2023 and completed at least VDZ induction. Baseline demographic characteristics, response at 12 months (m), need for optimization, and treatment persistence during follow-up were assessed. Logistic regression was used to evaluate predictors for response at 12m and treatment persistence. Results A total of 113 CD patients (57% male), mean age 52 years (range 18-87 years) were included. Colonic (47%) and ileal (29%) were the most frequent CD involvement. Inflammatory (68%) was the most frequent phenotype compared to stenosing (23%) and fistulizing (9%). Perianal involvement was present in 9% of patients. VDZ was indicated as first-line in 61 (54%) patients, second-line 31 (27.4%) patients, third line 17 (15%) patients, and fourth-line 4 (3.5%) patients. At 12 m of follow-up, clinical remission was observed in 37 (32.7%) patients and clinical response in 56 (49.6%) patients. Eighteen (15.9%) patients presented a lack of response/primary failure. Adverse effects leading to VDZ discontinuation prior to 12m occurred in 2 (1.8%) patients. Mean follow-up time in those patients that achieved clinical remission/response at 12m was 23 (SD 15) m. Thirty-five (37.6%) of those patients required dose optimization and 69 (74.2%) persisted on treatment during follow-up. Male sex (OR 2.93, 95%CI 1.04-8.26) and inflammatory phenotype (OR 5.37, 95%CI 1.16-24.9) were independent predictors for clinical response/remission at 12m. VDZ in first-line (OR 3, 95%CI 1.05-8.52) and inflammatory phenotype (OR 2.96, 95%CI 1.07-8.22) were independent predictors for treatment persistence in those patients that achieved clinical remission/response at 12m. Conclusion This is the first real-life multicenter study on the effectiveness of VZD in CD in Argentina and one of the largest in Latin America. VDZ showed an effective therapeutic option in a real-life setting. A higher efficacy was observed in males, inflammatory phenotype and in biologic-naïve patients.

What problem does this paper attempt to address?

This paper aims to address the issue regarding the practical application effect of vedolizumab (VDZ) in patients with Crohn's disease (CD). Specifically, the research objectives include: 1. **Describe the clinical characteristics of Crohn's disease patients receiving vedolizumab treatment**: This includes basic information such as the patient's age, gender, disease location, and disease phenotype. 2. **Understand the sequence of vedolizumab use in biologic agent treatment**: That is, whether vedolizumab is used in first - line, second - line, third - line, or fourth - line treatment. 3. **Evaluate the clinical response and treatment persistence of patients within one year**: By analyzing the clinical remission rate and clinical response rate of patients 12 months after treatment, as well as the durability of treatment, to evaluate the practical efficacy of vedolizumab. ### Background Vedolizumab is an integrin inhibitor that selectively acts on the intestine and is used to treat Crohn's disease. Currently, the efficacy data of vedolizumab in the real - world mainly come from studies in North America and Europe, while the relevant data in Latin America are relatively scarce. Therefore, this study fills this gap and provides detailed data for the Argentine patient population. ### Methods The study adopted a retrospective multi - center study design and included data from 18 Argentine centers. The study subjects were adult Crohn's disease patients aged 18 years and above. These patients started using vedolizumab between June 1, 2015, and October 31, 2023, and completed at least one induction - phase treatment. The study evaluated baseline demographic characteristics, clinical responses at 12 months, the need for dose optimization, and treatment persistence. Logistic regression analysis was used to evaluate the predictors of clinical response and treatment persistence at 12 months. ### Results - **Patient characteristics**: A total of 113 Crohn's disease patients (57% male) were included, with an average age of 52 years (range 18 - 87 years). The most common disease locations were the colon (47%) and the ileum (29%). The most common disease phenotype was the inflammatory type (68%), followed by the stenotic type (23%) and the fistulous type (9%). - **Treatment sequence**: Patients with vedolizumab as first - line treatment accounted for 54%, second - line treatment accounted for 27.4%, third - line treatment accounted for 15%, and fourth - line treatment accounted for 3.5%. - **Clinical response**: During the 12 - month follow - up, 32.7% of the patients achieved clinical remission, 49.6% of the patients had a clinical response, and 15.9% of the patients had no response or initial failure. The proportion of patients who discontinued treatment prematurely due to adverse reactions was 1.8%. - **Treatment persistence**: Among the patients who achieved clinical remission or response at 12 months, the average follow - up time was 23 months (standard deviation 15 months). 37.6% of the patients required dose optimization, and 74.2% of the patients continued to use vedolizumab during the follow - up period. - **Predictive factors**: Male (OR 2.93, 95% CI 1.04 - 8.26) and inflammatory phenotype (OR 5.37, 95% CI 1.16 - 24.9) were independent predictors of clinical response/remission at 12 months. Vedolizumab as first - line treatment (OR 3, 95% CI 1.05 - 8.52) and inflammatory phenotype (OR 2.96, 95% CI 1.07 - 8.22) were independent predictors of treatment persistence. ### Conclusion This is the first multi - center study in Argentina on the practical efficacy of vedolizumab in Crohn's disease patients and one of the largest related studies in Latin America. The results show that vedolizumab is an effective treatment option in practical applications, especially showing higher efficacy in male patients, those with an inflammatory phenotype, and those who have not used biologic agents.

P701 Evaluation of the effectiveness of vedolizumab in patients with Crohn's disease: a multicenter real-life study from Argentina

P558 Clinical Effectiveness and Safety of Vedolizumab vs. Infliximab in Biologic-Naïve Ulcerative Colitis Patients: A Brazilian Real-World Multicentric Observational Study

Effectiveness and safety of vedolizumab for ulcerative colitis: a single-center retrospective real-world study in China.

P990 A Multi-center, Single-arm, Prospective, Observational, Real-world Study in China to Evaluate Effectiveness of Vedolizumab in the Treatment of Inflammatory Bowel Diseases: First Interim Analysis of Patient-reported Outcomes

P922 A multicenter retrospective real-world study to determine the optimal cases of vedolizumab-treated UC patients

The effectiveness of vedolizumab in advanced therapy-experienced ulcerative colitis patients: Real world data from the Inflammatory Bowel Disease of the Middle East (IBD-ME) Registry group

P640 Role of vedolizumab trough levels in predicting clinical response in Inflammatory Bowel Disease: a multicentre prospective study

P674 Real-world experiences of switching to subcutaneous formulation in IBD patients on maintenance vedolizumab treatment

Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn’s disease patients: a German retrospective chart review

P809 VARIETY BEACH: Real-world treatment patterns for vedolizumab intravenous and subcutaneous maintenance dosing observed over 1 year in studies from Belgium, Austria and Switzerland

P627 Real-world clinical effectiveness and safety of vedolizumab and ustekinumab in biologic-naïve patients with Crohn’s disease by disease location: Results from the EVOLVE Expansion study

P776 A Prospective, Multicenter, Single-arm, Observational Study to Evaluate the Safety and Effectiveness of Vedolizumab in Real-world Clinical Practice in China: Interim Analysis of Safety results

Real-world Clinical Effectiveness and Safety of Vedolizumab and Adalimumab in Biologic-naive Patients With Crohn’s Disease

P625 Electronic patient-reported outcomes in Inflammatory Bowel Diseases on vedolizumab therapy: Interim analysis of the non-interventional German LISTEN II study

Open: Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium

P628 Vedolizumab in Indian patients with Inflammatory Bowel Disease: Interim results from a prospective, multicentre, open-label, phase 4 study

P527 Factors associated with choice of treatment regimen after the induction period in patients with Ulcerative Colitis treated with vedolizumab

Therapeutic Drug Monitoring as a Tool for the Clinical Outcome Prediction in Vedolizumab-Treated Patients: An Italian Pilot Study

P773 Clinical decision support tool for vedolizumab is useful in predicting endoscopic remission in Crohn's disease – a retrospective real-life single-centre cohort study

P629 Real-life treatment persistence and treatment outcomes of Finnish patients with Inflammatory Bowel Disease receiving vedolizumab as first-line biological treatment

P964 Vedolizumab trough concentrations during subcutaneous treatment in patients with inflammatory bowel diseases